The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).
 
Shreyas Joshi
Consulting or Advisory Role - Blue Earth Diagnostics; CG Oncology; enGene
Travel, Accommodations, Expenses - Ferring
 
Sam Chang
Consulting or Advisory Role - Astellas Pharma; CG oncology; enGene; Janssen; KDx Diagnostics; Lantheus Medical Imaging; Merck; Nonagen bioscience; Pacific Edge; Pfizer; Prokarium; Telix Pharmaceuticals; UroGen pharma; Valar Science; Vesica Health
 
Rian Dickstein
Employment - Chesapeake Urology
Honoraria - UroGPO
Consulting or Advisory Role - CG Oncology; Ferring; Johnson & Johnson/Janssen; Olympus; Photocure; Urogen pharma
Speakers' Bureau - Ferring; Urogen pharma
 
Gautam Jayram
Consulting or Advisory Role - Bristol-Myers Squibb; enGene; Ferring; Janssen; Merck; Telix Pharmaceuticals
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Jen-Jane Liu
Honoraria - OncLive
Consulting or Advisory Role - OmniCoil
 
Yair Lotan
Stock and Other Ownership Interests - Phinomics, Vessi Medical, CAPs medical, Nanorobot, Uroviu, C2i Genomics
Consulting or Advisory Role - Nanorobotics, Photocure, Astra-Zeneca, Merck, Fergene, Abbvie, Nucleix, Ambu, Seattle Genetics, Hitachi, Ferring Research, verity pharmaceutics, virtuoso surgical, Stimit, Urogen, Vessi medical, CAPs medical, Xcures, BMS, Nonagen, Aura Biosciences, Inc.,
Research Funding - Urogen, Seagen
 
Raj Satkunasivam
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer, Merck, CoImmune, UroGen, enGene, Photocure, Janssen
 
Anne Schuckman
Honoraria - CG Oncology; EnGene; pacific edge; Photocure
Consulting or Advisory Role - Fergene; Gerson Lehrman Group; Pacific Edge Biotechnology; Pacific Edge Biotechnology; Photocure
Speakers' Bureau - Photocure
 
Gary Steinberg
Stock and Other Ownership Interests - CG Oncology; enGene; Epivax Therapeutics
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; Aura Biosciences; Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; Imvax; MDxHealth; Merck; NanOlogy; Natera; Nonagen Bioscience; photocure; Roche/Genentech; Taris BioMedical; Verity Pharmaceuticals
 
John Taylor
No Relationships to Disclose
 
Tammy Linback
Employment - enGene
Stock and Other Ownership Interests - enGene
 
Raj Pruthi
Employment - enGene
Stock and Other Ownership Interests - enGene
 
James Sullivan
Employment - enGene
Stock and Other Ownership Interests - enGene
 
Christine Tosone
Employment - enGene
Stock and Other Ownership Interests - enGene
 
Ashish Kamat
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Aspira Women's Health (I); Astellas Pharma; AstraZeneca; CG Oncology; Cystotech; enGene; Ferring; Genentech; GlaxoSmithKline (I); ImmunityBio; Imvax; Janssen; Merck; Nonagen Bioscience; Pfizer; Seagen; Theralase; Valar Labs; Vivet Therapeutics
Research Funding - Arquer Diagnostics (Inst); enGene (Inst); FKD Therapies (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Photocure (Inst); Seagen (Inst); SWOG (Inst)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - Bladder Cancer Advocacy Network; European Urology Oncology; International Bladder Cancer Group (IBCG); Journal of Urology; UroToday